Informations générales (source: ClinicalTrials.gov)
Evaluation of the Clinical Specificity of Cellular and Molecular Biomarkers Identified in Patients With Lichen Planus
Interventional
N/A
Institut Pasteur (Voir sur ClinicalTrials)
novembre 2023
avril 2027
09 mai 2026
Lichen planus (LP) is a chronic inflammatory disease of unknown aetiology, affecting the
skin and mucous membranes, characterised by a CD8+ cytotoxic T-cell infiltrate,
associated with epithelial cell death and disruption of the basement membrane zone. In
previous work, T cell antigen receptor (TCR) repertoire studies were performed. In all
patients tested, whether with erosive or non-erosive LP, unique nucleotide sequences,
called clonotypes, have been identified. They appear during the process of TCR gene
rearrangement. These clonotypes are specific for human papillomavirus (HPV) in blood and
lesions, suggesting antigenic stimulation of these clonotypes by a viral epitope of HPV,
which crosses with an epitope on keratinocytes. The diagnosis of LP is made on the basis
of clinical and histological criteria, but in some patients and in some anatomical
locations, the diagnosis is difficult to make and LP may be confused with other skin
conditions.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP - Hôpital Avicenne | Frédéric Caux, Pr | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Saint Louis | Hervé Bachelez, Pr | Contact (sur clinicalTrials) | |||
| CDS DE L INSTITUT PASTEUR | Fabien Taieb, Dr | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hôpital Robert Debré, CHU de Reims - 51092 - Reims - France | Manuelle Viguier, Pr | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU de Besançon - 25030 - Besançon - France | François Aubin, Pr | Contact (sur clinicalTrials) | |||
| CHU de Rouen - Rouen - France | Pascal Joly, Pr | Contact (sur clinicalTrials) | |||
Critères
Tous
- Subject coming at the time of diagnosis of the disease before any systemic
treatment, or at the time of a progressive episode of the disease, without systemic
treatment or after cessation of immunomodulatory or immunosuppressive treatment
- Ability to give their consent in writing
- Must understand spoken and written French
- Affiliated to the French social security or assimilated regimes
Exclusion Criteria:
- Dermatosis exclusively localised in the skin folds or on the face (risk of scarring
from biopsies)